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Abstract
Purpose We investigated whether age at anastrozole
(A) initiation influences the effect of treatment on bone
mineral density (BMD). We conducted a post hoc analysis
of the dataset of Arimidex Bone Mass Index Oral Bis-
phosphonates prospective trial, studying the effect of
risedronate (R) on BMD of postmenopausal, early breast
cancer patients receiving A.
Methods Patients were stratified into those with normal
BMD or mild osteopenia (T [ -2) receiving A-only and
patients with mild or severe osteopenia (T B -2) or oste-
oporosis (T \ -2.5) receiving A and per os R (A ? R).
Depending on age on treatment initiation, patients were
grouped into two age cohorts, above and below 65 years.
BMD change in lumbar spine (LS) and hip (HP) was
evaluated at 12 months. An analysis of patients with nor-
mal BMD at baseline was additionally performed.
Results Among patients receiving A-only, women
B65 years were more likely to have a decrease in LS-BMD
than older (p = 0.034). HP-BMD decrease at 12 months
was not related to age (p = 0.182). In patients with mild or
severe osteopenia or osteoporosis, treated with A ? R, no
age effect was observed for LS or HP (p = 0.099 and
p = 0.939, respectively). Among patients with normal
BMD at baseline, the age effect on LS-BMD change was
more profound (p = 0.026).
Conclusions Our study suggests that younger postmeno-
pausal women with normal BMD or mild osteopenia
receiving A-only face an increased risk of bone loss in LS.
Among patients with mild or severe osteopenia or osteo-
porosis treated with A ? R, 12 months LS or HP BMD
variations were configured regardless of age group.
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Introduction
The principle treatment options for postmenopausal
patients with hormone receptor (HR)-positive breast cancer
are third-generation aromatase inhibitors (AIs) and selec-
tive estrogen receptor modulators (SERMs). Adjuvant
therapy with AIs has significant benefits over SERMs in
terms of disease-free survival and safety (Rugo 2008;
Baum et al. 2003; Coombes et al. 2004; Goss et al. 2005;
Gibson et al. 2009; Howell et al. 2005; Markopoulos 2010),
and it is recommended by International Scientific Associ-
ations (Burstein et al. 2010; Carlson et al. 2006; NCCN
2011; NICE 2009).
Breast cancer and treatment increases the risk of oste-
oporosis, falls, and fractures in women affected (Chen et al.
2005a, b, 2009; Kanis et al. 1999). AIs reduce systemic
estrogen through 98 % inhibition of the aromatase enzyme
(Geisler et al. 1996, 2002; Dixon et al. 2008), and this
estrogen deficiency is associated with an accelerated bone
loss. Bisphosphonates (BPs) are considered effective sup-
portive therapy in the decrease in skeletal complications in
different types of cancers, including breast cancer (Body
et al. 1998; Aapro et al. 2008; Markopoulos et al. 2010).
BPs inhibit bone resorption by interfering with osteoclast
activation and by promoting osteoclast apoptosis (Body
et al. 1998; Fleisch 2002; Ashcroft et al. 2003; Gnant and
Eidtmann 2010). Clinical evidence supports their use as
add-ons to AIs as a protective measure against osteoporosis
(Gnant et al. 2007; Brufsky et al. 2009; Bundred et al.
2008; Lester et al. 2008; Van et al. 2010).
Our group recently published the results of the Arimidex
Bone Mass Index and Oral Bisphosphonates (ARBI) mul-
ticenter, prospective, open-label study on the effect of the
BP risedronate on BMD in postmenopausal, early breast
cancer patients scheduled to receive anastrozole (Marko-
poulos et al. 2010). The ARBI study demonstrated that
postmenopausal patients with normal BMD before starting
anastrozole had a low risk of developing osteoporosis
during the first 2 years of treatment. Furthermore, risedr-
onate co-administration significantly increased BMD levels
in patients with pre-treatment osteopenic to osteoporotic
status (Markopoulos et al. 2010).
It is still not known, however, whether AIs affect bone
density in the same way within different age groups of
postmenopausal women. This is particularly interesting
because estrogen deficiency leads to bone density decreases
with age: every year, 1 of 3 women above 65 years has a fall
and sustains fractures (ESHRE Capri Workshop Group
2010; Sambrook and Cooper 2006; Khosla et al. 1997), and
65 years of age is an indication for measuring BMD in
osteoporosis guidelines (National Osteoporosis Foundation
2010; O’Neill et al. 2004; Papaioannou et al. 2010).
Furthermore, recent research results indicate that younger
patients on A treatment may face risk of increased bone-
resorption rates (Powell et al. 2011).
In this context, we conducted this post hoc analysis




The ARBI study was multicenter, prospective, open-label
study on the effect of the BP risedronate on BMD in
postmenopausal, early breast cancer patients scheduled to
receive anastrozole (Trial registration: ClinicalTrials.gov
Identifier NCT00809484).
Patients were to have undergone primary surgery and
chemotherapy (if indicated). Exclusion criteria were drug-
induced menopause, evidence of metastatic bone disease,
previous hip fractures or prostheses, bone metabolism
disorders, untreated hypocalcemia, previous treatment with
selective estrogen receptor modulators, hormone-replace-
ment therapy, or bisphosphonates (BPs), and liver or renal
dysfunction. All women received Anastrozole (Ari-
midexTM AstraZeneca, London, UK) 1 mg/day and were
followed up for 24 months. All patients had to give
informed consent prior to enrollment in the study. Full
local ethics committee approval was successfully obtained
in all sites recruiting patients for the study, and national
ethics committee approval of the trial protocol was also
obtained. The design and results of the ARBI trial have
been previously reported (Markopoulos et al. 2010).
Patient groups
A total of 213 postmenopausal patients with HR-positive
breast cancer were enrolled into the ARBI study.
Participants were assigned to three risk groups (Fig. 1)
for developing aromatase inhibitor-associated bone loss
based on their baseline BMD T-score measured in lumbar
spine (LS) and hip (HP):
• low risk with a normal T-score C-1 at both sites
• mild-to-moderate risk with T-score \-1 at either site
and [-2 at both sites
• high risk with a T-score B-2 at either site.
Patients in low risk group (n = 50) with normal BMD at
baseline (T-score C -1 at both sites) received treatment
with Anastrozole alone. The medium risk group (n = 70)
was randomized to receive Risedronate in addition to
Anastrozole (n = 37) or Anastrozole alone (n = 33), and
Risedronate (35 mg/week) was administered to all high
risk patients (n = 93).
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Additionally, all patients on study received daily sup-
plements of Vitamin D (400 IU/day) and Calcium
(1,000 mg/day). This is because it is known that older,
postmenopausal women are at increased risk of developing
vitamin D insufficiency because they may have inadequate
intakes of vitamin D as well as of calcium, and additionally
skin cannot synthesize the vitamin efficiently by aging
(Institute of Medicine, Food and Nutrition Board 2010). As
calcium is necessary for maintaining bone health and
vitamin D is important for the absorption of calcium from
the stomach, supplements were given to prevent as possible
the effect that their insufficient intake would have had on
BMD and influence the effect of medicines under study.
Assessments
The primary endpoint of the ARBI study was to investigate
the effect of R in the randomized arms measured in both LS
and HP at 12 months. BMD levels were evaluated at
baseline before anastrozole administration, at 12, and at
24 months (secondary endpoint), by dual-energy X-ray
absorptiometry (DEXA).
Patient demographic data, Eastern Cooperative Oncol-
ogy Group (ECOG) Performance Status (Oken et al. 1982),
and fracture history were recorded at baseline.
Formulation of the post hoc statistical analysis
The aim of this unplanned subgroup analysis was to
explore whether age at baseline differentiates the effect of
A on BMD change at 12 months post-treatment initiation.
Depending on age on treatment initiation, patients were
grouped into two age cohorts above and below 65 years,
since this is the threshold for measuring BMD in osteo-
porosis guidelines (National Osteoporosis Foundation
2010; O’Neill et al. 2004; Papaioannou et al. 2010).
In the present analysis, we stratified the ARBI study
patients (low risk treated with A-only, moderate with or
without R and high risk with R) into two groups according
to the administration or not of Risedronate: (a) patients
with normal BMD or mild osteopenia (T [ -2) receiving
A-only and (b) patients with mild or severe osteopenia
(T B -2) or osteoporosis (T \ -2.5) receiving A and per
os R (A ? R). The classification of patients as described
above is presented in Fig. 1.
The outcome measure of change at 12 months post-
treatment initiation was calculated as the ratio 12 m/base-
line and expressed as percentage. Comparisons between the
age groups were performed using the t test. 95 % confi-
dence intervals (CI) for changes as well as for the differ-
ence between changes are reported in all cases in order to
Fig. 1 Schema of the post hoc
age subgroup analysis.
A, anastrozole; R, Risedronate;




J Cancer Res Clin Oncol (2012) 138:1569–1577 1571
123
facilitate the assessment of the clinical significance of the
findings.
Since baseline BMD levels may affect the temporal
variation of BMD, we also performed a covariance analysis
using baseline BMD as a confounding factor for the effect
of age to account for possible predisposition bias caused by
baseline imbalances on BMD (interaction effect). All sta-
tistical tests were evaluated at the 5 % level of significance.
Results
Of all patients, 54.5 % (116/213) were 65 years or younger
and 45.5 % (97/213) were older (Table 1). The ECOG
status was 0 for nearly all B65-year-old patients (% range:
97.9–100.0) and for most [65-year-old patients (% range:
75.0–77.0). Seven patients had sustained traumatic fractures
3–56 years before study enrollment, none of the LS or HP.
Figure 2a shows the average percent BMD change from
baseline and the 95 % CI for LS and HP in patients with
normal BMD or mild osteopenia at baseline receiving
treatment with A-only. Mean BMD percent change in LS
was -5.8 % (95 % CI: -9.5 %, -2.1 %) for patients B65
and -0.5 % (95 % CI: -3.7 %, 2.6 %) for patients [65.
The difference in density loss of 5.3 % (95 % CI: 0.4 %,
10.1 %) between the age groups was statistically significant
(p = 0.034, Table 1). Mean BMD percent change in HP
was -1.4 % (95 % CI: -5.9 %, 3.0 %) for patients B65
and -5.3 % (95 % CI: -8.5 %, -2.2 %) for patients[65.
The difference in density loss of 3.9 % (95 % CI: -1.9 %,
9.7 %) between the age groups was not statistically sig-
nificant (p = 0.182, Table 1).
In patients with mild or severe osteopenia or osteopo-
rosis receiving A ? R (Fig. 2B), mean BMD percent
change in LS was ?4.2 % (95 % CI: 1.5 %, 6.9 %) for
patients B65 and ?8.1 % (95 % CI: 4.0 %, 12.2 %) for
patients [65. The difference in density gain of 3.9 %
(95 % CI: -0.7 %, 8.5 %,) between the age groups was not
statistically significant (p = 0.099, Table 1). Mean BMD
percent change in HP was -0.2 % (95 % CI: -3.4 %,
2.9 %) for patients B65 and -0.4 % (95 % CI: -3.9 %,
3.1 %) for patients [65. The difference in density loss of
0.2 % (95 % CI: -4.5 %, 4.9 %) between the age groups
was not statistically significant (p = 0.939, Table 1).
Figure 3 shows the average percent BMD change from
baseline and the 95 % CI for LS and HP for the substratum
of 50 patients with normal BMD at baseline. Mean BMD
percent change in LS was -9.1 % (95 % CI: -13.2 %,
-5.1 %) for patients B65 and -2.6 % (95 % CI: -6.6 %,
1.3 %) for patients [65. The difference in density loss of
6.5 % (95 % CI: 0.8 %, 12.2 %) between the age groups
was statistically significant (p = 0.026, Table 2). Mean
Table 1 Patient baseline characteristics by age group and treatment strata
A A ? R Total
B65 [65 B65 [65 B65 [65
Age (years)
N 47 36 69 61 116 97
Mean ± SD 57 ± 4.7 71 ± 4.6 58 ± 4.1 72 ± 4.5 58 ± 4.4 72 ± 4.6
BMD LS
Mean ± SD 1.04 ± 0.12 1.02 ± 0.14 0.84 ± 0.14 0.80 ± 0.16 0.91 ± 0.16 0.88 ± 0.19
BMD HP
Mean ± SD 0.88 ± 0.13 0.84 ± 0.10 0.76 ± 0.09 0.71 ± 0.11 0.81 ± 0.12 0.76 ± 0.12
BMI
Mean ± SD 28.76 ± 5.51 29.57 ± 3.85 26.89 ± 5.02 28.62 ± 4.22 27.65 ± 5.28 28.97 ± 4.09
N (%)
ECOG status
0 46 (97.9) 27 (75.0) 69 (100.0) 47 (77.0) 115 (99.1) 74 (76.3)
1 1 (2.1) 9 (25.0) 0 (0.0) 14 (23.0) 1 (0.9) 23 (23.7)
Fracture history
No 41 (87.2) 35 (97.2) 67 (97.1) 54 (88.5) 108 (93.1) 89 (91.8)
Yesa 3 (6.4) 0 (0.0) 1 (1.4) 3 (4.9) 4 (3.4) 3 (3.1)
Not reported 3 (6.4) 1 (2.8) 1 (1.4) 4 (6.6) 4 (3.4) 5 (5.2)
A anastrozole, R risedronate, BMD bone mineral density, BMI body mass index, ECOG eastern cooperative oncology group, SD standard
deviation
a Traumatic fractures only; between 3 and 56 years before enrollment in the study; none in the hip (HP) or lumbar spine (LS)
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BMD percent change in HP was -3.8 % (95 % CI:
-7.4 %, -0.2 %) for patients B65 and -3.9 % (95 % CI:
-6.8 %, -1.1 %) for patients [65. The difference in
density loss of 0.1 % (95 % CI: -4.7 %, 5.0 %) between
the age groups was not statistically significant (p = 0.957,
Table 2).
Covariance analysis examined whether the effect of age
is truly caused by differences in baseline BMD (Table 3).
The age effect on LS changes at 12 months in patients with
normal BMD or mild osteopenia at baseline remained
statistically significant even after adjustment by baseline
BMD values (p = 0.0295). Moreover, the estimate of the
adjusted difference was almost identical to the unadjusted
(-5.147 and -5.3 %, respectively). The negative effect of
baseline BMD value on LS changes at 12 months is sta-
tistically significant in both treatment groups (A and
A ? R, p value = 0.0098 and p value \ 0.001, respec-
tively). This means that patients with higher baseline BMD
levels are more likely to present larger loss or smaller
increase at 12 months compared with patients with smaller
baseline BMD levels. However, regarding HP, no statisti-
cally significant associations were detected (Table 3;
results are shown without the interaction effect that was not
significant).
Discussion
We conducted this post hoc analysis of the ARBI dataset to
evaluate the difference in BDM changes between age
groups. Our results indicate that women [65 years are
more likely to experience larger increases or smaller
decreases in their LS-BMD levels than women B65 years.
In HP, no statistically significantly differences were
recorded between age groups.
In patients with normal BMD or mild osteopenia at
baseline receiving treatment with A-only, our observation
of a systematic deterioration in BMD levels in patients
Fig. 2 a Average BMD change from baseline at lumbar spine (LS) by
age group, in patients on Anastrozole-only (A) and on Anastrozole
plus Risedronate (A ? R). b Average BMD change from baseline at
hip (HP) by age group, in patients receiving Anastrozole-only (A) or
Anastrozole plus Risedronate (A ? R)
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B65 years could be possibly attributed to greater skeletal
changes occurring in younger patients when receiving
anastrozole. This greater change in BMD when anastrozole
is administered to younger women was shown by Powell
et al. 2011. They compared the levels of the bone-resorp-
tion marker uNTx (urinary cross-linked N-telopeptide of
type I collagen) in newly diagnosed women with breast
cancer who were receiving anastrozole and were above or
below the age of 70 years with that of healthy women of
the same age group (\70 or C70 years). The group of
younger women had statistically significantly higher levels
of the bone-resorption marker compared with their healthy
counterparts, while the older age group had similar levels
compared with healthy women. The uNTx levels in
younger women on anastrozole were similar to those
in elderly women, both healthy and on anastrozole. In
younger women, uNTx exceeded normal levels but not in
older women. This could be attributed to higher levels of
free estradiol in younger, postmenopausal women, which
allows for more marked effects with the aromatase inhib-
itors (Powell et al. 2011). Supporting data from the liter-
ature show that there is a decline in free estradiol levels
Fig. 3 Average BMD change at lumbar spine (LS) and hip (HP) by age group, in 50 patients with normal BMD at baseline, receiving A-only
Table 2 Average BMD change from baseline (95 % CI) by age group at 12 months
B65 [65 Difference p value
Based on treatment
LS
A -5.8 % (-9.5 %, -2.1 %) -0.5 % (-3.7 %, 2.6 %) 5.3 % (0.4 %, 10.1 %) 0.034
A ? R 4.2 % (1.5 %, 6.9 %) 8.1 % (4.0 %, 12.2 %) 3.9 % (-0.7 %, 8.5 %) 0.099
HP
A -1.4 % (-5.9 %, 3.0 %) -5.3 % (-8.5 %, -2.2 %) 3.9 % (-1.9 %, 9.7 %) 0.182
A ? R -0.2 % (-3.4 %, 2.9 %) -0.4 % (-3.9 %, 3.1 %) 0.2 % (-4.5 %, 4.9 %) 0.939
Patients (N = 50) with normal BMD at baseline, receiving A alone
LS -9.1 % (-13.2 %, -5.1 %)a -2.6 % (-6.6 %, 1.3 %)b 6.5 % (0.8 %, 12.2 %) 0.026
HP -3.8 % (-7.4 %, -0.2 %)c -3.9 % (-6.8 %, -1.1 %)d 0.1 % (-4.7 %, 5.0 %) 0.957
LS lumbar spine, HP hip, A anastrozole, R risedronate, BMD bone mineral density, CI confidence interval
a N = 20; b N = 14; c N = 21; d N = 14
Table 3 Covariance analysis, age effect on the percent change from
baseline adjusted by baseline BMD values
Effect LS HP
Estimate p value Estimate p value
A
Age (B 65 vs. [ 65) -0.05147 0.0295 0.03734 0.1996
Baseline BMD -0.2551 0.0098 -0.2029 0.0997
A ? R
Age (B 65 vs. [ 65) 0.02446 0.2649 -0.00425 0.8595
Baseline BMD -0.2917 \0.0001 -0.05986 0.4432
LS lumbar spine, HP hip, A anastrozole, R risedronate, BMD bone
mineral density
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with aging (Bjornerem et al. 2004); this seems to be caused
by a rise of sex hormone globulin levels found in elderly
women rather than due to decreased levels of total estradiol
in this age group (Sharp et al. 1996; Laughlin et al. 2000).
However, differences in the degree of BMD change caused
by anastrozole between elderly breast cancer patients and
their younger counterparts could also be due to some
extend to a different sensitivity of hormone receptors to
circulating estradiol, developed by aging. This hypothesis
needs further investigation.
Comparing the anastrozole effect on LS and HP, in the
ATAC (Eastell et al. 2006) as well as in the SABRE trial
(Van Poznak et al. 2010), anastrozole significantly reduced
BMD of both LS and HP; notably, in both trials, patients
showed a greater BMD loss in the lumbar region (LS) than
at femoral sites (HP). In our study, results are in the same
direction with the above trials, although changes in HP
were not statistically significant in our study population;
anastrozole had a negative effect on femoral BMD as well,
whereas risedronate was shown that can prevent this BMD
loss (Table 2; Fig. 2a). This difference in the degree of
BMD change according to sites (LS and HP) could be
attributed to different sensitivity of receptors to AI-induced
estrogen deprivation of lumbar region and femoral sites
with advancing age.
Crivellari et al. 2008 investigated differences in
response to letrozole treatment and adverse events by age
groups but did not assess bone marker profiles, only bone
fractures, which were similar across different age groups.
The ATAC trial (Arimidex Tamoxifen Alone or in Com-
bination) showed greater BMD losses in anastrozole-
treated women who experienced menopause within the last
4 years than in those who were more than 4 years post-
menopausal (Eastell et al. 2006). A subsequent analysis of
the same study for the investigation of potential risk factors
for joint symptoms showed no detectable effect of age
(Sestak et al. 2008).
Our literature search did not retrieve any other studies
comparing the impact of AIs on bone marker profile
measurements depending on the age of the patient. Our
results and those published by Powell et al. 2011 indicate
the need for age group comparison of bone markers and
further evaluation of the impact the AIs have on different
age groups of patients. AIs have been found to have higher
efficacy than Tamoxifen (Rugo 2008; Baum et al. 2003;
Coombes et al. 2004; Goss et al. 2005; Gibson et al. 2009;
Howell et al. 2005; Markopoulos 2010), and there is a
general recommendation for the administration of an AI at
some point during the adjuvant hormonal treatment of
postmenopausal patients with hormone receptor positive
early breast cancer (Burstein et al. 2010). However, there is
concern about the negative effect they have on BMD in
contrast to Tamoxifen and this is important for both,
younger postmenopausal women losing bone mass due to
recent menopause and aging, and elderly women often
having already osteopenia-osteoporosis but different life
expectancy. Therefore, it is very important to explore
possible differences in the effect that AIs might have on
BMD according to age of patients and to BMD status
before the administration of an AI, so appropriate sup-
portive measures could be taken in clinical practice.
Moreover, our findings render the general perception to
feel ‘‘safe’’ considering ‘‘bone loss’’ when starting adjuvant
treatment with an AI in patients having normal BMD
before treatment, questionable. Maybe young, postmeno-
pausal patients starting AI treatment should be followed for
BMD changes, especially in LS, despite normal BMD at
baseline.
Notably, our results are limited by the fact that this is an
unplanned subgroup analysis of the ARBI trial, and they
were not powered to investigate such hypothesis. Despite
this, they do indicate that a future study aiming to explicitly
address this specific issue of age-related BMD changes in
postmenopausal breast cancer patients on adjuvant treat-
ment with AIs is justified.
In conclusion, our results suggest that among patients
with normal BMD or mild osteopenia receiving A-only,
younger women face an increased risk of BMD loss in LS
12 months post-treatment initiation, especially if they
present with normal BMD. Among patients with mild or
severe osteopenia or osteoporosis, AI treatment side effect
on BMD is not related to age group.
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